Managed Healthcare Executive September 19, 2024
When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Physicians inside and outside of Medicare could lose at least $25 billion in add-on payments for Part B drugs that could be part of the Inflation Reduction Act’s program to negotiate drugs, according to an analysis conducted by Avalere. This analysis, which was funded by the Community Oncology Alliance (COA), found that the physicians most likely to be impacted are oncologists.
“Any provider who administers any of the oncology or hematology products on the list may see some of the largest decreases,” Milena Sullivan, a managing director with a background in oncology policy and...
Today's Sponsors
Today's Sponsor